Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRX215 after hepatectomy for colorectal liver metastases
2025-523630-59-00Phase 2Authorised
- Sponsor
- HepaRegeniX GmbH
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of darizmetinib in colorectal cancer liver metastasis (CRLM) (4 arms), sponsored by HepaRegeniX GmbH. Primary endpoints: Incidence, severity, and relatedness of adverse events and serious adverse events, Change from baseline in vital signs and physical examination findings and 2 more. Planned start Jun 2026; status: authorised.
02
Drugs
darizmetinib
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2025-523630-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523630-59-00.